These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 16109168

  • 1. In vivo antimuscarinic actions of the third generation antihistaminergic agent, desloratadine.
    Howell G, West L, Jenkins C, Lineberry B, Yokum D, Rockhold R.
    BMC Pharmacol; 2005 Aug 18; 5():13. PubMed ID: 16109168
    [Abstract] [Full Text] [Related]

  • 2. The involvement of muscarinic receptor subtypes in the mediation of hypothermia, tremor, and salivation in male mice.
    Sánchez C, Lembøl HL.
    Pharmacol Toxicol; 1994 Jan 18; 74(1):35-9. PubMed ID: 8159635
    [Abstract] [Full Text] [Related]

  • 3. Central and peripheral mediation of hypothermia, tremor and salivation induced by muscarinic agonists in mice.
    Sánchez C, Meier E.
    Pharmacol Toxicol; 1993 Jan 18; 72(4-5):262-7. PubMed ID: 8372044
    [Abstract] [Full Text] [Related]

  • 4. Centrally active antimuscarinic analogs of oxotremorine selectively block physostigmine-induced hypertension, but not peripheral muscarinic vasodepression.
    Vargas HM, Ringdahl B.
    J Pharmacol Exp Ther; 1990 Apr 18; 253(1):165-70. PubMed ID: 2329503
    [Abstract] [Full Text] [Related]

  • 5. Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1 receptor antagonist. 2nd communication: lack of central nervous system and cardiovascular effects.
    Kreutner W, Hey JA, Chiu P, Barnett A.
    Arzneimittelforschung; 2000 May 18; 50(5):441-8. PubMed ID: 10858871
    [Abstract] [Full Text] [Related]

  • 6. The effects of antihistamines with varying anticholinergic properties on voluntary and involuntary movement.
    Naicker P, Anoopkumar-Dukie S, Grant GD, Kavanagh JJ.
    Clin Neurophysiol; 2013 Sep 18; 124(9):1840-5. PubMed ID: 23643576
    [Abstract] [Full Text] [Related]

  • 7. Anticholinergic effects of desloratadine, the major metabolite of loratadine, in rabbit and guinea-pig iris smooth muscle.
    Cardelús I, Antón F, Beleta J, Palacios JM.
    Eur J Pharmacol; 1999 Jun 18; 374(2):249-54. PubMed ID: 10422766
    [Abstract] [Full Text] [Related]

  • 8. Effects of first and second generation antihistamines on muscarinic induced mucus gland cell ion transport.
    Liu H, Farley JM.
    BMC Pharmacol; 2005 Mar 24; 5():8. PubMed ID: 15790419
    [Abstract] [Full Text] [Related]

  • 9. Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1 receptor antagonist. 1st communication: receptor selectivity, antihistaminic activity, and antiallergenic effects.
    Kreutner W, Hey JA, Anthes J, Barnett A, Young S, Tozzi S.
    Arzneimittelforschung; 2000 Apr 24; 50(4):345-52. PubMed ID: 10800633
    [Abstract] [Full Text] [Related]

  • 10. Regional differences in receptor reserve for analogs of oxotremorine in vivo: implications for development of selective muscarinic agonists.
    Ringdahl B, Roch M, Jenden DJ.
    J Pharmacol Exp Ther; 1987 Aug 24; 242(2):464-71. PubMed ID: 3612545
    [Abstract] [Full Text] [Related]

  • 11. The central and peripheral effectiveness of two oxotremorine-antagonists determined using oxotremorine-induced tremor and salivation.
    Eicholzer A, Ogren SO.
    J Pharm Pharmacol; 1977 Oct 24; 29(10):609-11. PubMed ID: 21240
    [Abstract] [Full Text] [Related]

  • 12. Serotonergic potentiation of muscarinic agonist evoked tremor and salivation in rat and mouse.
    Ogren SO, Carlsson S, Bartfai T.
    Psychopharmacology (Berl); 1985 Oct 24; 86(3):258-64. PubMed ID: 3929296
    [Abstract] [Full Text] [Related]

  • 13. Nonmuscarinic neurotoxicity of oxotremorine.
    Witkin JM, Alvarado-Garcia R, Lee MA, Witkin KM.
    J Pharmacol Exp Ther; 1987 Apr 24; 241(1):34-41. PubMed ID: 3572794
    [Abstract] [Full Text] [Related]

  • 14. Cholinergic M2 muscarinic receptor-mediated inhibition of endogenous noradrenaline release from the isolated vascularly perfused rat stomach.
    Yokotani K, Osumi Y.
    J Pharmacol Exp Ther; 1993 Jan 24; 264(1):54-60. PubMed ID: 8423550
    [Abstract] [Full Text] [Related]

  • 15. Phenyl-substituted analogues of oxotremorine as muscarinic antagonists.
    Nilsson BM, Vargas HM, Ringdahl B, Hacksell U.
    J Med Chem; 1992 Jan 24; 35(2):285-94. PubMed ID: 1732545
    [Abstract] [Full Text] [Related]

  • 16. Absence of anticholinergic activity of rolipram, an antidepressant with a novel mechanism of action, in three different animal models in vivo.
    Wachtel H, Löschmann PA, Pietzuch P.
    Pharmacopsychiatry; 1988 Sep 24; 21(5):218-21. PubMed ID: 3227052
    [Abstract] [Full Text] [Related]

  • 17. Novel alkoxy-oxazolyl-tetrahydropyridine muscarinic cholinergic receptor antagonists.
    Shannon HE, Bymaster FP, Hendrix JC, Quimby SJ, Mitch CH.
    Psychopharmacology (Berl); 1995 Jan 24; 117(2):208-15. PubMed ID: 7753969
    [Abstract] [Full Text] [Related]

  • 18. Differential response to cholinergic stimulation in psychogenitically selected rat lines.
    Martin JR, Driscoll P, Gentsch C.
    Psychopharmacology (Berl); 1984 Jan 24; 83(3):262-7. PubMed ID: 6433388
    [Abstract] [Full Text] [Related]

  • 19. Meperidine does not block the cholinergic effects of oxotremorine.
    Leander JD.
    Pharmacol Biochem Behav; 1979 Jun 24; 10(6):941-2. PubMed ID: 482317
    [Abstract] [Full Text] [Related]

  • 20. Alterations in behavioral responses to a cholinergic agonist in post-pubertal rats with neonatal ventral hippocampal lesions: relationship to changes in muscarinic receptor levels.
    Laplante F, Nakagawasai O, Srivastava LK, Quirion R.
    Neuropsychopharmacology; 2005 Jun 24; 30(6):1076-87. PubMed ID: 15637638
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.